Recruiting
Hodgkin's disease
RecruitingStudy of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma
Registered drugNo placebo
Study of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma
Registered drugNo placebo
- Disease:Hodgkin's disease
- Substances:Brentuximab VedotinDacarbazine+6
Countries:
Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Brentuximab Vedotin
- Sponsor:Polska Grupa Badawcza Chloniakow
